The Medical Letter on Drugs and Therapeutics
COVID-19 Update: Bebtelovimab EUA Withdrawn (online only)
Download PDF:   US English
Med Lett Drugs Ther. 2022 Dec 26;64(1666):e209
 Select a term to see related articles  bebtelovimab   COVID-19   Lagevrio   molnupiravir   nirmatrelvir   Paxlovid   remdesivir   remdesivir   Ritonavir   Veklury 

The FDA has withdrawn its Emergency Use Authorization (EUA) of the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab (LY-CoV1404 – Lilly) for treatment of COVID-19. Bebtelovimab is not expected to retain activity against the Omicron variants BQ.1, BQ.1.1, and XBB, which currently cause the majority of COVID-19 cases in all regions of the US.1-3

The NIH currently recommends treating high-risk nonhospitalized adults with COVID-19 with either oral ritonavir-boosted nirmatrelvir (Paxlovid) or IV remdesivir (Veklury); Paxlovid is preferred.4 Both of these therapies decreased the risk of hospitalization or death significantly more than placebo in large, randomized, double-blind trials.5,6 If these drugs are inappropriate or unavailable, use of oral molnupiravir (Lagevrio; available under an EUA) is recommended.4,7 Ritonavir-boosted nirmatrelvir, remdesivir, and molnupiravir are expected to retain activity against SARS-CoV-2 variants BQ.1, BQ.1.1, and XBB.1

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article